CGRP mAb therapies show good effectiveness post-approval in chronic migraine

Results presented at AHS 2020 suggest that, in a real-world setting, calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapies show the effectiveness that might be expected from clinical trial results. However, when patients need to switch from one CGRP mAb therapy to another, the results are often disappointing.